BRCA1 and BRCA2 Gene Mutation Detection Kit ( Reversible Terminator Sequencing)    

Primary DI

06974968583162

Basic UDI-DI Code

B-06974968583162

Reference

L000043

Device Types

None provided

Regulation

Eu Ivdd

Classification

Eu Ivd General

Status

On The Market

Manufacturer

GeneMind Biosciences Co., Ltd.

BRCA1 and BRCA2 genes are tumor suppressor genes involved in DNA damage repair and transcriptional regulation. Studies have shown that the sensitivity of tumor cells with BRCA1/2 gene mutations to PARP inhibitors is significantly higher than that of normal cells. Inhibiting the activity of PARP-1 can lead to synthetic lethality in tumor cells with BRCA1/2 gene mutations. Poly ADP-ribose polymerase 1 (PARP-1) plays an important role in DNA damage repair and apoptosis. Tumor cells with BRCA1 and BRCA2 gene mutations often rely on PARP-1 to complete the repair of DNA damage. Therefore, PARP inhibitors can targetedly kill tumor cells with BRCA1/2 gene mutations by inhibiting the function of PARP-1. Clinical studies have shown that ovarian or breast cancer patients with BRCA1 or BRCA2 gene mutations can benefit from the treatment of PARP inhibitors such as Olaparib and Rubraca.

Other on-the-market devices with the same classification (Eu Ivd General) and regulation (EU IVDD).